Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - BIOMARIN PHARMACEUTICAL INC | d389958d8k.htm |
Exhibit 99.1
| Contact: | ||||
| Investors Eugenia Shen BioMarin Pharmaceutical Inc. (415) 506-6570 |
Media Bob Purcell BioMarin Pharmaceutical Inc. (415) 506-3267 | |||
For Immediate Release:
BioMarin Announces Second Quarter 2012 Financial Results
Strong Commercial Performance Supporting Development of Five New Chemical Entities
With Multiple Key Clinical Readouts by the End of 2012
Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited)
| Item |
Q2 2012 | Q2 2011 | Percent Change |
|||||||||
| Total BioMarin Revenue |
$ | 124.0 | $ | 110.6 | 12.1 | % | ||||||
| Total Net Product Revenue |
123.0 | 109.6 | 12.2 | % | ||||||||
| Naglayzme Net Product Revenue* |
62.9 | 60.3 | 4.3 | % | ||||||||
| Aldurazyme BioMarin Net Product Revenue |
21.8 | 17.3 | 26.0 | % | ||||||||
| Kuvan Net Product Revenue |
34.7 | 28.8 | 20.5 | % | ||||||||
| Firdapse Net Product Revenue |
3.6 | 3.2 | 12.5 | % | ||||||||
| GAAP Net Loss |
(32.0 | ) | (5.1 | ) | ||||||||
| GAAP Net Loss per Share (basic and diluted) |
$ | (0.27 | ) | $ | (0.05 | ) | ||||||
| Non-GAAP Adjusted EBITDA Income (Loss) |
(7.3 | ) | 13.9 | |||||||||
| * | Naglazyme net product revenue for the second quarter of 2012 compared to the second quarter of 2011 was negatively impacted by $1.0 million (or 2.5% of sales) due to changes in foreign currency exchange rates, net of hedges, and was also affected by the timing of government ordering patterns. Naglazyme net product revenue for the first half of 2012 has increased by approximately 9% compared to the first half of 2011, which is proportionate to the number of new patients that initiated commercial therapy over the last year. |
Novato, Calif., August 1, 2012 – BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced financial results for the second quarter of 2012. GAAP net loss was $32.0 million ($0.27 per share) for the second quarter of 2012, compared to GAAP net loss of $5.1 million ($0.05 per share) for the second quarter of 2011. Non-GAAP adjusted EBITDA was a loss of $7.3 million for the second quarter of 2012, compared to non-GAAP adjusted EBITDA gain of $13.9 million for the second quarter of 2011. Non-GAAP adjusted EBITDA excludes depreciation and amortization, contingent consideration expense, interest income and expense, income taxes, stock compensation expense and material non-recurring items. The reconciliation of the non-GAAP measures to the comparable GAAP measure is detailed in the table provided near the end of the press release.
GAAP net loss for the six months ended June 30, 2012 was $56.0 million ($0.48 per share), compared to GAAP net loss of $9.4 million ($0.09 per share) for the six months ended June 30, 2011. Non-GAAP adjusted EBITDA was a loss of $7.2 million for the six months ended June 30, 2012, compared to non-GAAP adjusted EBITDA gain of $32.9 million for the six months ended June 30, 2011.
As of June 30, 2012, BioMarin had cash, cash equivalents and short and long-term investments totaling $524.6 million, as compared to $287.7 million on March 31, 2012. During the second quarter of 2012, BioMarin completed a public offering of common stock with net proceeds of approximately $235 million.
“Our commercial portfolio continued to perform well in the second quarter, and revenue generated from our products is helping to fund a large portion of our pipeline programs,” said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. “The successful and timely execution of our R&D pipeline remains our top priority as we look forward to several key clinical program readouts in the coming months. In addition to the results of the Phase 3 GALNS trial, we also expect to have results from three Phase 2 programs—PEG-PAL for PKU, BMN-701 for Pompe disease, and BMN-673 for solid tumors.”
1
Net Product Revenue (in millions)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||
| 2012 | 2011 | $ Change | % Change | 2012 | 2011 | $ Change | % Change | |||||||||||||||||||||||||
| Naglazyme (1) |
$ | 62.9 | $ | 60.3 | $ | 2.6 | 4.3 | % | $ | 131.5 | $ | 120.9 | $ | 10.6 | 8.8 | % | ||||||||||||||||
| Kuvan (2) |
34.7 | 28.8 | 5.9 | 20.5 | % | 66.7 | 55.5 | 11.2 | 20.2 | % | ||||||||||||||||||||||
| Firdapse (3) |
3.6 | 3.2 | 0.4 | 12.5 | % | 7.2 | 6.3 | 0.9 | 14.3 | % | ||||||||||||||||||||||
| (1) | Changes in foreign currency rates, net of hedges, had a negative $1.0 million and a negative $1.2 million impact on Naglazyme sales in the three and six months ended June 30, 2012, compared to the same periods in 2011, respectively. Naglazyme revenues experience quarterly fluctuations due to the timing of government ordering patterns in certain countries. |
| (2) | The quantity of commercial tablets dispensed to patients in the U.S. increased 16.9 percent in the second quarter of 2012 compared to the second quarter of 2011. |
| (3) | A product for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS) which was launched in the EU in April 2010. |
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||
| 2012 | 2011 | $ Change | % Change | 2012 | 2011 | $ Change | % Change | |||||||||||||||||||||||||
| Aldurazyme revenue reported by Genzyme (4) |
$ | 45.8 | $ | 44.5 | $ | 1.3 | 2.9 | % | $ | 91.7 | $ | 87.2 | $ | 4.5 | 5.2 | % | ||||||||||||||||
| Royalties due from Genzyme |
18.4 | 17.3 | 1.1 | 36.8 | 34.0 | 2.8 | ||||||||||||||||||||||||||
| Incremental product transfer revenues (5) |
3.4 | — | 3.4 | (3.0 | ) | 2.0 | (5.0 | ) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| Total Aldurazyme net product revenues |
$ | 21.8 | $ | 17.3 | $ | 4.5 | $ | 33.8 | $ | 36.0 | $ | (2.2 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| (4) | The total number of Aldurazyme patients increased 8.0 percent in the second quarter of 2012 as compared to the second quarter of 2011. |
| (5) | To the extent units shipped to third party customers by Genzyme exceed BioMarin inventory transfers to Genzyme, BioMarin will record a decrease in net product revenue from the royalty payable to BioMarin for the amount of previously recognized product transfer revenue. If BioMarin inventory transfers exceed units shipped to third party customers by Genzyme, BioMarin will record incremental net product transfer revenue for the period. |
2012 Guidance
| Revenue Guidance ($ in millions) |
||||
| Item |
2012 Guidance | Previous 2012 Guidance | ||
| Total BioMarin Revenues |
Unchanged | $475 to $510 | ||
| Total Net Product Revenues |
Unchanged | $470 to $505 | ||
| Naglazyme Net Product Revenue |
Unchanged | $250 to $265 | ||
| Kuvan Net Product Revenue |
$130 to $140 | $126 to $136 | ||
| Aldurazyme Net Product Revenue to BioMarin |
Unchanged | $81 to $87 | ||
| Firdapse Net Product Revenue |
Unchanged | $13 to $17 | ||
| Selected Income Statement Guidance ($ in millions) |
||||
| Item |
2012 Guidance | Previous 2012 Guidance | ||
| Cost of Sales (% of Total Revenue) |
Unchanged | 17% to 18% | ||
| Selling, General and Admin. Expense |
Unchanged | $195 to $205 | ||
| Research and Development Expense |
$285 to $295 | $265 to $275 | ||
| Amortization and Contingent Consideration |
Unchanged | $19 | ||
| Income Tax Expense |
Unchanged | $— | ||
| GAAP Net (Loss) |
$ (115) to (105) | $(92) to $(82) | ||
| Stock Compensation Expense |
$50 | $46 | ||
| Non-GAAP Adjusted EBITDA |
$(5) to $5 | $15 to $25 | ||
| Non GAAP Net Cash Flow (Usage) |
$(40) to $(50) | $(30) to $(40) | ||
| Cash Balance* |
$475 to $485 | $250 to $260 | ||
2
| * | Cash balance includes cash, cash equivalents and short and long term investments |
Anticipated Upcoming Milestones
3Q 2012: Results for Phase II trial for PEG-PAL for PKU
3Q 2012: Results for Phase I trial for BMN-111 for achondroplasia in healthy volunteers
4Q 2012: Results for Phase III trial for GALNS for MPS IVA
4Q 2012: Results for Phase I/II trial for BMN-673 for solid tumors
1Q 2013: Market authorization application filing for GALNS for MPS IVA
1Q 2013: Results for Phase I/II trial for BMN-701 for Pompe disease
1H 2013: IND filing for BMN-190 for LINCL (Batten disease)
2Q 2013: Potential initiation of Phase III trial for PEG-PAL for PKU
2Q 2013: Results for PKU-016 Kuvan neurocognitive study
2H 2013: Potential initiation of Phase III trial for BMN-673 for solid tumors
4Q 2013: Potential FDA approval of GALNS for MPS IVA
Research and Development Programs
BioMarin continues to make significant investments in research and development to ensure a strong and profitable pipeline for the company. The current pipeline includes programs in various stages of development that focus on treating a range of rare and serious unmet medical needs.
Advanced Clinical Programs
| • | GALNS for MPS IVA: The company is on track to report top-line results in the fourth quarter of 2012. Additionally, the company has begun three ancillary studies, in part to support future reimbursement discussions: a clinical trial for patients under five years of age and a cardiopulmonary study to more completely document the health benefits of GALNS are both enrolling, and a study in patients with limited ambulation is expected to start enrolling patients imminently. |
Mid-Stage Clinical Programs
| • | PEG-PAL for PKU: In the ongoing Phase II study, the rate of discontinuation due to adverse events remains low and virtually all patients who are able to achieve a therapeutic dose have their blood Phe levels lowered to less than 600 µmol/L, the target of therapeutic efficacy. The company is conducting Part D of the Phase II trial to characterize the safety of a shorter weekly induction regimen prior to switching over to the daily maintenance dose. Results are expected at the end of this quarter. |
| • | Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is now fully enrolled. Endpoints include clinically validated measures of neuropsychiatric symptoms and, if successful, may enable a label amendment. The company expects to report top-line results in the second quarter of 2013. |
Early-Stage Clinical Programs
| • | BMN-701 for Pompe Disease: The company has continued dosing patients in the 20 mg/kg cohort of the Phase I/II trial using the new material from the 12,000L process. The company expects to complete enrollment of 15 patients in the 20 mg/kg cohort by early August. BMN-701 has been generally well-tolerated with a safety profile consistent with other enzyme replacement therapies. Top-line results for the Phase I/II trial are expected in the first quarter of 2013. |
| • | BMN-673 (PARP inhibitor): Over 20 patients have been dosed in the Phase I/II open-label trial on once daily, orally administered BMN-673 for advanced or recurrent solid tumors, and the company has not yet determined the maximum tolerated dose. Top-line results for this study are expected in the fourth quarter of 2012. |
| • | BMN-111 for Achondroplasia: BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth. The company expects to report results for the Phase I study in the third quarter of 2012. |
3
Preclinical Programs
| • | BMN-190 for LINCL (Batten disease): BioMarin expects to file the IND for BMN-190 in the first half of 2013. Recent meetings with regulatory authorities have been encouraging and suggest a possible aggressive clinical and regulatory path to approval. |
| • | Other early stage programs: BioMarin is working on multiple additional early development opportunities. |
Non-GAAP Financial Information and Reconciliation
The above results for the three and six months ended June 30, 2012 and June 30, 2011 and financial guidance for the year ending December 31, 2012 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) adjusted to exclude non-cash stock compensation expense, contingent consideration expense and certain nonrecurring material items (Non-GAAP Adjusted EBITDA).
The following table presents the reconciliation of non-GAAP to GAAP financial metrics:
Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA Income (Loss)
(in millions)
(unaudited)
| NOTES | Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||||||
| GAAP Net Loss |
$ | (32.0 | ) | $ | (5.1 | ) | $ | (56.0 | ) | $ | (9.4 | ) | ||||||||
| Interest expense, net |
1.4 | 1.3 | 2.8 | 2.6 | ||||||||||||||||
| Income tax expense (benefit) |
(0.4 | ) | 3.9 | (0.4 | ) | 8.7 | ||||||||||||||
| Depreciation |
7.2 | 6.3 | 14.5 | 12.7 | ||||||||||||||||
| Amortization |
2.7 | 1.0 | 12.0 | 1.9 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| EBITDA Income (Loss) |
(21.1 | ) | 7.4 | (27.1 | ) | 16.5 | ||||||||||||||
| Stock-based compensation |
12.6 | 10.6 | 23.8 | 21.0 | ||||||||||||||||
| Contingent consideration |
(1 | ) | 1.2 | (4.1 | ) | (3.9 | ) | (4.6 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Non-GAAP Adjusted EBITDA Income (Loss) |
$ | (7.3 | ) | $ | 13.9 | $ | (7.2 | ) | $ | 32.9 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| (1) | Represents the changes in the fair value of contingent acquisition consideration payable for the period. The change in the current quarter reflects changes in estimated probabilities and timing of achieving certain developmental milestones. |
BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin’s GAAP information because it provides additional information regarding the performance of BioMarin’s core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors’ overall understanding of the company’s business and prospects for the future. Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses the Non-GAAP Adjusted EBITDA methodology in establishing corporate goals for internal compensation programs.
Conference Call Details
BioMarin will host a conference call and webcast to discuss second quarter 2012 financial results today, Wednesday, August 1, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.
Date: August 1, 2012
4
Time: 5:00 p.m. ET
U.S. / Canada Dial-in Number: 800 299.7089
International Dial-in Number: 617 801.9714
Participant Code: 93633766
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 76241046
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-nutriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia. For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.
Forward-Looking Statement
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, Firdapse, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin’s clinical trials of GALNS, Firdapse, PEG-PAL, BMN-673, BMN-701, BMN-111 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation’s success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN-673, BMN-701 and BMN-111; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono’s activities related to Kuvan; and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s 2011 Annual Report on Form 10-K, and the factors contained in BioMarin’s reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
5
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2012 and December 31, 2011
(In thousands of U.S. dollars, except share and per share amounts)
| June 30, 2012 |
December 31, 2011(1) |
|||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 177,757 | $ | 46,272 | ||||
| Short-term investments |
224,829 | 148,820 | ||||||
| Accounts receivable, net (allowance for doubtful accounts: $471 and $513, respectively) |
100,750 | 104,839 | ||||||
| Inventory |
120,125 | 130,118 | ||||||
| Other current assets |
58,073 | 39,753 | ||||||
|
|
|
|
|
|||||
| Total current assets |
681,534 | 469,802 | ||||||
| Investment in BioMarin/Genzyme LLC |
1,185 | 559 | ||||||
| Long-term investments |
121,970 | 94,385 | ||||||
| Property, plant and equipment, net |
267,374 | 268,971 | ||||||
| Intangible assets, net |
168,267 | 180,277 | ||||||
| Goodwill |
51,543 | 51,543 | ||||||
| Long-term deferred tax assets |
220,593 | 222,649 | ||||||
| Other assets |
20,061 | 15,495 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 1,532,527 | $ | 1,303,681 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable and accrued liabilities |
$ | 96,557 | $ | 94,125 | ||||
| Convertible debt |
23,440 | — | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
119,997 | 94,125 | ||||||
| Long-term convertible debt |
324,865 | 348,329 | ||||||
| Other long-term liabilities |
87,239 | 88,179 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
532,101 | 530,633 | ||||||
|
|
|
|
|
|||||
| Stockholders’ equity: |
||||||||
| Common stock, $0.001 par value: 250,000,000 shares authorized at June 30, 2012 and December 31, 2011: 123,235,882 and 114,789,732 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively. |
123 | 115 | ||||||
| Additional paid-in capital |
1,483,336 | 1,197,082 | ||||||
| Company common stock held by Nonqualified Deferred Compensation Plan |
(6,604 | ) | (3,935 | ) | ||||
| Accumulated other comprehensive income |
4,650 | 4,887 | ||||||
| Accumulated deficit |
(481,079 | ) | (425,101 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
1,000,426 | 773,048 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 1,532,527 | $ | 1,303,681 | ||||
|
|
|
|
|
|||||
| (1) | December 31, 2011 balances were derived from the audited consolidated financial statements. |
6
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Three and Six Months Ended June 30, 2012 and 2011
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)
| Three Months Ended June 30 |
Six Months Ended June 30, |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| REVENUES: |
||||||||||||||||
| Net product revenues |
$ | 122,991 | $ | 109,616 | $ | 239,230 | $ | 218,692 | ||||||||
| Collaborative agreement revenues |
423 | 153 | 519 | 278 | ||||||||||||
| Royalty and license revenues |
605 | 862 | 919 | 1,117 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenues |
124,019 | 110,631 | 240,668 | 220,087 | ||||||||||||
| OPERATING EXPENSES: |
||||||||||||||||
| Cost of sales (excludes amortization of certain acquired intangible assets) |
23,574 | 19,263 | 40,679 | 40,059 | ||||||||||||
| Research and development |
77,812 | 52,909 | 151,646 | 97,889 | ||||||||||||
| Selling, general and administrative |
51,539 | 41,015 | 96,787 | 82,089 | ||||||||||||
| Intangible asset amortization and contingent consideration |
2,048 | (3,324 | ) | 4,376 | (3,012 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
154,973 | 109,863 | 293,488 | 217,025 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| INCOME (LOSS) FROM OPERATIONS |
(30,954 | ) | 768 | (52,820 | ) | 3,062 | ||||||||||
| Equity in the income (loss) of BioMarin/Genzyme LLC |
102 | (667 | ) | (632 | ) | (1,209 | ) | |||||||||
| Interest income |
536 | 798 | 1,041 | 1,580 | ||||||||||||
| Interest expense |
(1,925 | ) | (2,201 | ) | (3,872 | ) | (4,364 | ) | ||||||||
| Other income and (expense) |
(176 | ) | 129 | (140 | ) | 151 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| INCOME (LOSS) BEFORE INCOME TAXES |
(32,417 | ) | (1,173 | ) | (56,423 | ) | (780 | ) | ||||||||
| Provision for (benefit from) income taxes |
(411 | ) | 3,904 | (445 | ) | 8,668 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| NET LOSS |
$ | (32,006 | ) | $ | (5,077 | ) | $ | (55,978 | ) | $ | (9,448 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| NET LOSS PER SHARE, BASIC AND DILUTED |
$ | (0.27 | ) | $ | (0.05 | ) | $ | (0.48 | ) | $ | (0.09 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding, basic and diluted |
117,912 | 111,114 | 116,496 | 110,884 | ||||||||||||
| COMPREHENSIVE LOSS |
$ | (29,868 | ) | $ | (5,213 | ) | $ | (56,215 | ) | $ | (15,559 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
STOCK-BASED COMPENSATION EXPENSE
Total stock-based compensation expense included in the Condensed Consolidated Statements of Comprehensive Loss is as follows:
| Three Months Ended June 30, |
Six
Months Ended June 30, |
|||||||||||||||
| 2012 (unaudited) |
2011 (unaudited) |
2012 (unaudited) |
2011 (unaudited) |
|||||||||||||
| Cost of sales |
$ | 1,335 | $ | 1,127 | $ | 2,207 | $ | 2,529 | ||||||||
| Research and development |
5,468 | 4,024 | 10,290 | 7,698 | ||||||||||||
| Selling, general and administrative |
5,834 | 5,456 | 11,268 | 10,760 | ||||||||||||
|
|
|
|
|
|
|
|||||||||||
| $ | 12,637 | $ | 10,607 | $ | 23,765 | $ | 20,987 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
###
7